person · Reporting owner
FORMELA JEAN FRANCOIS
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImageneBio, Inc.IKNA · Entity 7139 | Director | June 07, 2024 | June 10, 2024 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 14, 2022 | June 16, 2022 |
| Korro Bio, Inc.KRRO · Entity 6388 | Director | September 11, 2026 | September 15, 2026 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | August 17, 2021 | August 18, 2021 |
| Translate Bio, Inc.TBIO · Entity 135439 | Director | September 14, 2021 | September 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImageneBio, Inc.
Report date June 07, 2024 · Filed June 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2034-06-06 | Direct | 17,520 |
Reported balance
After 2024-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-07 · Grant · Acquired 17,520 · Balance 17,520 F1: This option shall vest in full upon the earlier of (i) June 7, 2025 or (ii) the date of the next annual meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director. F2: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full upon the earlier of (i) June 7, 2025 or (ii) the date of the next annual meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director.
F2: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Intellia Therapeutics, Inc.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,291 |
Reported balance
After 2022-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-14 · Grant · Acquired 5,197 · Balance 7,291 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.49 · Expires 2032-06-13 | Direct | 7,688 |
Reported balance
After 2022-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-14 · Grant · Acquired 7,688 · Balance 7,688 F2: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. F3: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
F3: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Korro Bio, Inc.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 672,498 |
Reported balance
After 2026-09-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-11 · Sale · Disposed 8,450 · Balance 672,498 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 139,252 |
Reported balance
After 2026-09-11 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-11 · Sale · Disposed 1,750 · Balance 139,252 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 640,610 |
Reported balance
After 2026-09-14 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-14 · Sale · Disposed 31,888 · Balance 640,610 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 132,650 |
Reported balance
After 2026-09-14 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-14 · Sale · Disposed 6,602 · Balance 132,650 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
F4: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Spero Therapeutics, Inc.
Report date August 17, 2021 · Filed August 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.69 · Expires 2031-08-17 | Direct | 7,500 |
Reported balance
After 2021-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-17 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date. F2: The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership to the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date.
F2: The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership to the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Translate Bio, Inc.
Report date September 14, 2021 · Filed September 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-09-14 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-09-14 · Sale · Disposed 2,055,063 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. F2: 1,872,115 of these shares are held directly by Atlas Venture Fund VIII, L.P. ("Atlas VIII''). 182,948 of these shares are held directly by Atlas Venture Associates VIII, L.P. ("AVA VIII LP"), the general partner of Atlas VIII. These shares were previously received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas VIII. Atlas Venture Associates VIII, Inc. ("AVA VIII INC") is the sole general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII and Atlas VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to be an admission that Dr. Formela is the beneficial owner of such shares for the purposes of Section 16 or any other purpose. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2029-06-17 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-14 · Sale · Disposed 18,900 · Balance 0 F3: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F4: This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020. F5: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.33 · Expires 2030-06-15 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-14 · Sale · Disposed 18,900 · Balance 0 F3: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F6: This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021. F5: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.43 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-09-14 · Sale · Disposed 20,000 · Balance 0 F3: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F7: This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. F5: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.34 · Expires 2028-03-06 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-14 · Sale · Disposed 37,800 · Balance 0 F3: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F8: This option was granted on March 7, 2018, with 25% of the shares underlying the option vesting on March 7, 2019 and thereafter 2.0833% vesting monthly until March 7, 2022. F5: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
F2: 1,872,115 of these shares are held directly by Atlas Venture Fund VIII, L.P. ("Atlas VIII''). 182,948 of these shares are held directly by Atlas Venture Associates VIII, L.P. ("AVA VIII LP"), the general partner of Atlas VIII. These shares were previously received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas VIII. Atlas Venture Associates VIII, Inc. ("AVA VIII INC") is the sole general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII and Atlas VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to be an admission that Dr. Formela is the beneficial owner of such shares for the purposes of Section 16 or any other purpose.
F3: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F4: This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020.
F5: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
F6: This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.
F7: This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.
F8: This option was granted on March 7, 2018, with 25% of the shares underlying the option vesting on March 7, 2019 and thereafter 2.0833% vesting monthly until March 7, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 15, 2026 20:15 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 6,602 | $14.12 | $93,220.24 |
DisclosureSEC source: 0001030575-26-000014 · form4-09152026_040901.xml · nonDerivative · entry 4 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 132,650 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 20:15 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 31,888 | $14.12 | $450,258.56 |
DisclosureSEC source: 0001030575-26-000014 · form4-09152026_040901.xml · nonDerivative · entry 3 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 640,610 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:15 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 1,750 | $13.99 | $24,482.50 |
DisclosureSEC source: 0001030575-26-000014 · form4-09152026_040901.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 139,252 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:15 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 8,450 | $13.99 | $118,215.50 |
DisclosureSEC source: 0001030575-26-000014 · form4-09152026_040901.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 672,498 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:30 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 51 | $13.96 | $711.96 |
DisclosureSEC source: 0001030575-26-000012 · form4-08282026_040801.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 141,002 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.955 to $13.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:30 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 249 | $13.96 | $3,476.04 |
DisclosureSEC source: 0001030575-26-000012 · form4-08282026_040801.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 680,948 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.955 to $13.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:20 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 4,884 | $14.00 | $68,376.00 |
DisclosureSEC source: 0001030575-26-000010 · form4-08212026_080856.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 141,053 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:20 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 23,584 | $14.00 | $330,176.00 |
DisclosureSEC source: 0001030575-26-000010 · form4-08212026_080856.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 681,197 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 21:04 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 368 | $13.96 | $5,137.28 |
DisclosureSEC source: 0001030575-26-000008 · form4-08132026_090834.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 145,937 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 21:04 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 1,775 | $13.96 | $24,779.00 |
DisclosureSEC source: 0001030575-26-000008 · form4-08132026_090834.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 704,781 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 22:04 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 8,506 | $13.96 | $118,743.76 |
DisclosureSEC source: 0001030575-26-000006 · form4-07072026_100726.xml · nonDerivative · entry 4 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 146,305 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.05 inclusive. F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 22:04 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 817 | $13.96 | $11,405.32 |
DisclosureSEC source: 0001030575-26-000006 · form4-07072026_100726.xml · nonDerivative · entry 3 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 706,556 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.05 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 22:04 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 14,745 | $14.03 | $206,872.35 |
DisclosureSEC source: 0001030575-26-000006 · form4-07072026_100726.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 154,811 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5). F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 22:04 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 85,955 | $14.03 | $1,205,948.65 |
DisclosureSEC source: 0001030575-26-000006 · form4-07072026_100726.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 707,373 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5). F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 00:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 114 | $14.98 | $1,707.72 |
DisclosureSEC source: 0001030575-26-000004 · form4-06252026_120611.xml · nonDerivative · entry 8 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 169,556 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.97 to $15.10 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 00:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 6,979 | $14.60 | $101,893.40 |
DisclosureSEC source: 0001030575-26-000004 · form4-06252026_120611.xml · nonDerivative · entry 7 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 169,670 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.88 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 00:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 666 | $14.98 | $9,976.68 |
DisclosureSEC source: 0001030575-26-000004 · form4-06252026_120611.xml · nonDerivative · entry 6 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 793,328 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.97 to $15.10 inclusive. F2 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 00:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 40,679 | $14.60 | $593,913.40 |
DisclosureSEC source: 0001030575-26-000004 · form4-06252026_120611.xml · nonDerivative · entry 5 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 793,994 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.88 inclusive. F2 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 00:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 17,426 | $14.25 | $248,320.50 |
DisclosureSEC source: 0001030575-26-000004 · form4-06252026_120611.xml · nonDerivative · entry 4 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 176,649 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (4), (5) and (6). F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 00:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 101,579 | $14.25 | $1,447,500.75 |
DisclosureSEC source: 0001030575-26-000004 · form4-06252026_120611.xml · nonDerivative · entry 3 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 834,673 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (4), (5) and (6). F2 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 580 | $13.95 | $8,091.00 |
DisclosureSEC source: 0001030575-26-000004 · form4-06252026_120611.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 194,075 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 3,382 | $13.95 | $47,178.90 |
DisclosureSEC source: 0001030575-26-000004 · form4-06252026_120611.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 936,252 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F2 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 21:58 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 14,677 | $0.00 Strike: $10.59 | $0.00 |
DisclosureSEC source: 0001193125-26-267996 · ownership.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,677 Underlying: Common Stock · 14,677 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 21:35 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 419 | $13.95 | $5,845.05 |
DisclosureSEC source: 0001030575-26-000002 · form4-06012026_050601.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 194,655 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 21:35 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 2,441 | $13.95 | $34,051.95 |
DisclosureSEC source: 0001030575-26-000002 · form4-06012026_050601.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 939,634 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026. F2 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:23 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 6,010 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0000950170-25-085424 · ownership.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,010 Underlying: Common Stock · 6,010 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 21:25 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 5,190 | $0.00 Strike: $42.19 | $0.00 |
DisclosureSEC source: 0000950170-24-072564 · ownership.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,190 Underlying: Common Stock · 5,190 shares Expires 2034-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. F2 · ownership.direct: The Reporting Person is a member of Atlas XI and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:15 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 17,520 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000950170-24-071303 · ownership.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,520 Underlying: Common Stock · 17,520 shares Expires 2034-06-06 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 7, 2025 or (ii) the date of the next annual meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director. F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 21:25 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantCommon Stock | 17,857 | $56.00 | $999,992.00 |
DisclosureSEC source: 0001415889-24-011388 · form4-04232024_090441.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 195,074 F1 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 03, 2023 Filed Nov 8, 2023 02:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0000950170-23-060597 · ownership.xml · derivative · entry 3 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-11-02 F6 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date. F7 · ownership.direct: The Reporting Person is a member of Atlas XI and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 03, 2023 Filed Nov 8, 2023 02:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantCommon Stock | 177,217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-060597 · ownership.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 177,217 F4 · kind: Received in exchange for Legacy Korro common stock issued in the private placement completed immediately prior to the Merger. F4 · shares: Received in exchange for Legacy Korro common stock issued in the private placement completed immediately prior to the Merger. F4 · price: Received in exchange for Legacy Korro common stock issued in the private placement completed immediately prior to the Merger. F5 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 03, 2023 Filed Nov 8, 2023 02:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantCommon Stock | 942,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-060597 · ownership.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 942,075 F1 · kind: Received in exchange for (i) 3,000,000 shares of common stock, (ii) 4,000,000 shares of Series Seed 1 Preferred Stock, (iii) 2,000,000 shares of Series Seed 2 Preferred Stock, (iv) 1,538,462 shares of Series Seed 3 Preferred Stock, (v) 5,357,142 shares of Series A Preferred Stock and (vi) 3,064,273 shares of Series B Preferred Stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the "Merger Agreement") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. F2 · kind: (Continued from Footnote 1) Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. F1 · shares: Received in exchange for (i) 3,000,000 shares of common stock, (ii) 4,000,000 shares of Series Seed 1 Preferred Stock, (iii) 2,000,000 shares of Series Seed 2 Preferred Stock, (iv) 1,538,462 shares of Series Seed 3 Preferred Stock, (v) 5,357,142 shares of Series A Preferred Stock and (vi) 3,064,273 shares of Series B Preferred Stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the "Merger Agreement") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. F2 · shares: (Continued from Footnote 1) Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. F1 · price: Received in exchange for (i) 3,000,000 shares of common stock, (ii) 4,000,000 shares of Series Seed 1 Preferred Stock, (iii) 2,000,000 shares of Series Seed 2 Preferred Stock, (iv) 1,538,462 shares of Series Seed 3 Preferred Stock, (v) 5,357,142 shares of Series A Preferred Stock and (vi) 3,064,273 shares of Series B Preferred Stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the "Merger Agreement") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. F2 · price: (Continued from Footnote 1) Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("Associates XI") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("Associates XI LLC") is the general partner of Associates XI. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:30 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 17,520 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0000899243-23-015445 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,520 Underlying: Common Stock · 17,520 shares Expires 2033-06-09 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:33 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 7,688 | $0.00 Strike: $38.49 | $0.00 |
DisclosureSEC source: 0001209191-22-037598 · doc4.xml · derivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688 Underlying: Common Stock · 7,688 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. F3 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:33 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 5,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037598 · doc4.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,291 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 22:08 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 13,419 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0000899243-22-022238 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,419 Underlying: Common Stock · 13,419 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the Reporting Person, a director of the Issuer, resigns from the Board or otherwise ceases to service as a director. F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:43 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 13,419 | $0.00 Strike: $14.92 | $0.00 |
DisclosureSEC source: 0000899243-21-049693 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,419 Underlying: Common Stock · 13,419 shares Expires 2031-12-21 F1 · derivative.exercise_date: This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 01:29 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 5,959 | $14.00 | $83,426.00 |
DisclosureSEC source: 0001209191-21-069645 · doc4.xml · nonDerivative · entry 4 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,241,935 F3 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 01:29 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 8,330 | $14.64 | $121,951.20 |
DisclosureSEC source: 0001209191-21-069645 · doc4.xml · nonDerivative · entry 3 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,247,894 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive. F3 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:29 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 11,989 | $15.03 | $180,194.67 |
DisclosureSEC source: 0001209191-21-069645 · doc4.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,256,224 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). F3 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 23:23 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 37,800 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001209191-21-056045 · doc4.xml · derivative · entry 5 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,800 shares Expires 2028-03-06 F3 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F8 · derivative.exercise_date: This option was granted on March 7, 2018, with 25% of the shares underlying the option vesting on March 7, 2019 and thereafter 2.0833% vesting monthly until March 7, 2022. F5 · ownership.direct: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 23:23 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.43 | $0.00 |
DisclosureSEC source: 0001209191-21-056045 · doc4.xml · derivative · entry 4 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F3 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F7 · derivative.exercise_date: This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. F5 · ownership.direct: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 23:23 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $15.33 | $0.00 |
DisclosureSEC source: 0001209191-21-056045 · doc4.xml · derivative · entry 3 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stcok · 18,900 shares Expires 2030-06-15 F3 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F6 · derivative.exercise_date: This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021. F5 · ownership.direct: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 23:23 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001209191-21-056045 · doc4.xml · derivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,900 shares Expires 2029-06-17 F3 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F4 · derivative.exercise_date: This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020. F5 · ownership.direct: This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 23:23 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleCommon Stock | 2,055,063 | $38.00 | $78,092,394.00 |
DisclosureSEC source: 0001209191-21-056045 · doc4.xml · nonDerivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. F1 · shares: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. F2 · ownership.nature: 1,872,115 of these shares are held directly by Atlas Venture Fund VIII, L.P. ("Atlas VIII''). 182,948 of these shares are held directly by Atlas Venture Associates VIII, L.P. ("AVA VIII LP"), the general partner of Atlas VIII. These shares were previously received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas VIII. Atlas Venture Associates VIII, Inc. ("AVA VIII INC") is the sole general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII and Atlas VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to be an admission that Dr. Formela is the beneficial owner of such shares for the purposes of Section 16 or any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 20:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0000899243-21-033456 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date. F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership to the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 13:48 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 6,149 | $143.45 | $882,074.05 |
DisclosureSEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 18 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,000 F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021 F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $143.32 - $144.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (19) of this Form 4. F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 13:48 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 13,556 | $142.88 | $1,936,881.28 |
DisclosureSEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 17 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,149 F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021 F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $142.32 - $143.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (18) of this Form 4. F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 13:48 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,420 | $141.66 | $1,192,777.20 |
DisclosureSEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 16 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 29,705 F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021 F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $141.32 - $142.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (17) of this Form 4. F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 13:48 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,027 | $140.80 | $1,130,201.60 |
DisclosureSEC source: 0001104659-21-086607 · tm2120917-1_4seq1.xml · nonDerivative · entry 15 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 38,125 F1 · security: Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021 F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $140.32 - $141.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (16) of this Form 4. F20 · ownership.nature: Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.